In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal-Making Trends

Set Alert for Deal-Making Trends

RNA Medicines: Advancements Leading To Investments

Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.

Outlook 2023 Growth

The Busiest Dealmakers Of 2022

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.

Outlook 2023 M & A

Deals In Depth: October 2022

Two $1bn+ alliances were penned in October. Financing reached $7.7bn in biopharma, $636m in device, and $140m in diagnostics.

Deals Financing

Deals Shaping The Medical Industry, October 2022

In Vivo's deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in October 2022. Data provided by Biomedtracker.

Financing Deals

Medtech Challenged To Build On 2021 Amid Threats Of Recession: Views From Industry Leaders

Strong headwinds beset the medtech industry as 2022 draws to a close, including supply chain, fundraising and labor shortages. However, optimism prevailed among medtech industry leaders discussing EY’s annual Pulse of the Industry medical technology report and related topics at AdvaMed’s 2022 MedTech Conference.

Financing Business Strategies

Accenture's Petra Jantzer On Changing M&A Strategies

In this episode of the In Vivo podcast, David Wild speaks with Petra Jantzer, senior managing director and global life sciences lead at Accenture, about the changing deals landscape. The discussion centers on the shifts in M&A strategies that Jantzer has been seeing among big pharmas and the need for other companies to adapt to a world in which technologies and processes become a key focus of growth.

Business Strategies Commercial

Dealmaking Quarterly Statistics, Q3 2022

During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.

Deals Companies

Financing Quarterly Statistics, Q3 2022

During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.

Deals Financing

Deals In Depth: September 2022

Just one $1bn+ alliance was penned in September compared to eight that were signed in August.

Deals Financing

Deals Shaping The Medical Industry, September 2022

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2022. Data provided by Biomedtracker.

Deals Financing

Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future

Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.

Financing Deals

Deals In Depth: August 2022

The height of the summer saw eight $1bn plus deals penned, including those by Pfizer and Roche.

Deals Financing
See All
UsernamePublicRestriction

Register